CL2020001480A1 - Métodos para obtener células derivadas de músculo. - Google Patents

Métodos para obtener células derivadas de músculo.

Info

Publication number
CL2020001480A1
CL2020001480A1 CL2020001480A CL2020001480A CL2020001480A1 CL 2020001480 A1 CL2020001480 A1 CL 2020001480A1 CL 2020001480 A CL2020001480 A CL 2020001480A CL 2020001480 A CL2020001480 A CL 2020001480A CL 2020001480 A1 CL2020001480 A1 CL 2020001480A1
Authority
CL
Chile
Prior art keywords
methods
derived cells
obtaining muscle
obtaining
smdc
Prior art date
Application number
CL2020001480A
Other languages
English (en)
Inventor
Marco Thurner
Eva Margreiter
Wolfgang Schwaiger
Faheem Muhammad Asim
Rainer Marksteiner
Original Assignee
Innovacell Biotechnologie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60923243&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2020001480(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innovacell Biotechnologie Ag filed Critical Innovacell Biotechnologie Ag
Publication of CL2020001480A1 publication Critical patent/CL2020001480A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/71—Oxidoreductases (EC 1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C12N2509/10—Mechanical dissociation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

La presente invención se refiere a métodos para obtener células derivadas del músculo esquelético (SMDC) y al uso de SMDC en un método para prevenir y/o tratar neuromiopatías y/o miopatías, en donde la neuromiopatía y/o miopatía es incontinencia, en particular una incontinencia urinaria y/o anal o fecal.
CL2020001480A 2017-12-14 2020-06-03 Métodos para obtener células derivadas de músculo. CL2020001480A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17207417 2017-12-14

Publications (1)

Publication Number Publication Date
CL2020001480A1 true CL2020001480A1 (es) 2020-10-30

Family

ID=60923243

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001480A CL2020001480A1 (es) 2017-12-14 2020-06-03 Métodos para obtener células derivadas de músculo.

Country Status (23)

Country Link
US (2) US11617768B2 (es)
EP (2) EP3724319B1 (es)
JP (2) JP7361398B2 (es)
KR (2) KR102780297B1 (es)
CN (1) CN111448307B (es)
AU (1) AU2018383015B2 (es)
CL (1) CL2020001480A1 (es)
CY (1) CY1126049T1 (es)
DK (1) DK3724319T3 (es)
ES (1) ES2948712T3 (es)
FI (1) FI3724319T3 (es)
HR (1) HRP20230474T1 (es)
HU (1) HUE062005T2 (es)
IL (2) IL309687A (es)
LT (1) LT3724319T (es)
MX (1) MX2020005881A (es)
PL (1) PL3724319T3 (es)
PT (1) PT3724319T (es)
RS (1) RS64241B1 (es)
SI (1) SI3724319T1 (es)
SM (1) SMT202300147T1 (es)
WO (1) WO2019115790A1 (es)
ZA (1) ZA202002410B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL286509B1 (en) 2019-03-22 2026-04-01 Innovacell Gmbh Methods for obtaining induced smooth muscle cells
JP7550778B2 (ja) * 2019-09-30 2024-09-13 テルモ株式会社 Ｃｄ５６陽性細胞の比率を高めるための方法
US20250114405A1 (en) 2021-08-06 2025-04-10 Innovacell Gmbh Myogenic progenitor cells for use in an optimized method for the prevention and treatment of anal incontinence
CN120283042A (zh) 2022-12-01 2025-07-08 苏黎世大学 肌肉前体细胞(mpc)大规模培养物的制备方法及其用途
KR102858797B1 (ko) * 2022-12-08 2025-09-12 주식회사 팡세 근육줄기세포의 분화능 예측을 위한 cd56의 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130141A (en) 1988-05-24 1992-07-14 Law Peter K Compositions for and methods of treating muscle degeneration and weakness
US5538722A (en) 1989-06-13 1996-07-23 Stanford University Isolation, growth, differentiation and genetic engineering of human muscle cells
HK1052645B (en) 2000-04-14 2008-03-20 Universtiy Of Pittsburgh Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof
JPWO2003027281A1 (ja) 2001-09-20 2005-01-06 協和醗酵工業株式会社 骨格筋間質由来多分化能幹細胞
CN103230415B (zh) * 2003-04-25 2016-05-04 匹兹堡大学联邦制高等教育 用于促进和增强神经修复和再生的肌肉来源的细胞（mdc）
FR2890977A1 (fr) * 2005-09-19 2007-03-23 Assist Publ Hopitaux De Paris Procede d'obtention de cellules musculaires lisses humaines et leurs applications
TW200736399A (en) * 2006-01-10 2007-10-01 Theradigm Inc Expansion and differentiation of neural stem cells under low oxygen conditions
CA2722758C (en) * 2007-05-29 2017-04-25 Thomas Payne Bone augmentation utilizing muscle-derived progenitor compositions, and treatments thereof
EP2206774A1 (en) 2008-12-23 2010-07-14 Genzyme Corporation Muscle-derived cells having differentiation capacities
EP2898089A1 (en) * 2012-09-24 2015-07-29 Innovacell Biotechnologie AG Potency assay for skeletal muscle derived cells
CN106350480B (zh) * 2016-08-26 2019-11-08 中国农业科学院北京畜牧兽医研究所 一种纯化牛胎儿骨骼肌组织来源成肌细胞的方法
IL286509B1 (en) 2019-03-22 2026-04-01 Innovacell Gmbh Methods for obtaining induced smooth muscle cells
US20250114405A1 (en) * 2021-08-06 2025-04-10 Innovacell Gmbh Myogenic progenitor cells for use in an optimized method for the prevention and treatment of anal incontinence

Also Published As

Publication number Publication date
JP7361398B2 (ja) 2023-10-16
KR102780297B1 (ko) 2025-03-12
BR112020011853A2 (pt) 2020-11-24
CA3085483A1 (en) 2019-06-20
JP2021506285A (ja) 2021-02-22
EP4223872A2 (en) 2023-08-09
FI3724319T3 (fi) 2023-05-04
IL275288A (en) 2020-07-30
JP7494430B2 (ja) 2024-06-04
SMT202300147T1 (it) 2023-07-20
HRP20230474T1 (hr) 2023-07-21
ES2948712T3 (es) 2023-09-18
RU2020120580A (ru) 2022-01-14
EP4223872A3 (en) 2023-08-23
US20230285467A1 (en) 2023-09-14
IL309687A (en) 2024-02-01
IL275288B1 (en) 2026-03-01
PT3724319T (pt) 2023-06-07
PL3724319T3 (pl) 2023-07-24
RS64241B1 (sr) 2023-06-30
US20210069255A1 (en) 2021-03-11
CY1126049T1 (el) 2023-11-15
US11617768B2 (en) 2023-04-04
CN111448307B (zh) 2025-03-25
AU2018383015A1 (en) 2020-05-28
JP2023085507A (ja) 2023-06-20
KR20250026373A (ko) 2025-02-25
ZA202002410B (en) 2021-09-29
LT3724319T (lt) 2023-06-12
CN111448307A (zh) 2020-07-24
KR20200099173A (ko) 2020-08-21
DK3724319T3 (da) 2023-05-01
EP3724319A1 (en) 2020-10-21
SI3724319T1 (sl) 2023-07-31
HUE062005T2 (hu) 2023-09-28
MX2020005881A (es) 2020-08-13
WO2019115790A1 (en) 2019-06-20
EP3724319B1 (en) 2023-04-05
AU2018383015B2 (en) 2025-02-27

Similar Documents

Publication Publication Date Title
CL2020001480A1 (es) Métodos para obtener células derivadas de músculo.
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
AR114283A1 (es) Receptores quiméricos de dll3 y métodos para su uso
MX394474B (es) Métodos de pronóstico para cáncer de vejiga sin invasión muscular y antagonistas para usarse en el tratamiento de lo mismo.
MX2021011816A (es) Metodos para produccion de celulas car-nk y uso de las mismas.
CO2019012473A2 (es) Antagonistas del receptor de hidrocarburos de arilo y usos de los mismos
MX2019008872A (es) Prevencion y tratamiento de da?o o enfermedad osea y cartilago.
EA201491617A1 (ru) Соединения для лечения спинальной мышечной атрофии
AR097032A1 (es) Hidrogeles de poli(alquenilamida)-polisacárido para el tratamiento de formaciones subterráneas
CL2017002283A1 (es) Formulaciones de anticuerpos y métodos (divisional de solicitud n°1081-2014)
MX2020001406A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
ECSP13013084A (es) Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del síntoma tumores de células b
BR112013014119A8 (pt) Novos moduladores e métodos de uso
CL2018000107A1 (es) Moléculas de anticuerpo que se unen a cd79
CL2021001829A1 (es) Anticuerpos anti–cd40 para el uso en el tratamiento de hidradenitis supurativa
PE20220297A1 (es) Neutralizacion del virus chikungunya mediada por anticuerpos
MX375177B (es) Inserto vaginal.
MX2014015806A (es) Composiciones colorantes para cabello que comprenden 2-metoximetil-1,4-diaminobenceno y 5-amino-4-cloro-o-cresol, metodos, y estuches que comprenden las composiciones.
MX2017006953A (es) Medicamentos para disminuir la evolucion de la enfermedad de parkinson.
MX2022001449A (es) Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos.
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
HRP20260273T1 (hr) Pripravak i spremnik, komplet, postupak uporabe
BR112018071600A2 (pt) métodos, composições e usos relacionados aos mesmos
MX2022015854A (es) Sistemas y metodos para mitigar la interferencia dentro del espectro usado activamente.
CL2018003167A1 (es) Selección de cepas bacterianas útiles en el tratamiento de alergias.